Therapy Detail

Therapy Name OSE 2101
Therapy Description

OSE 2101 is an DNA vaccine consisting of epitopes from CEA, ERBB2 (Her2), TP53, and MAGE 2/3, which may stimulate anti-tumor immunity (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
OSE 2101 EP-2101|Tedopi|OSE-2101|OSE2101 OSE 2101 is an DNA vaccine consisting of epitopes from CEA, ERBB2 (Her2), TP53, and MAGE 2/3, which may stimulate anti-tumor immunity (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT02654587 Phase III OSE 2101 Docetaxel + Pemetrexed Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC (ATALANTE 1) Recruiting